KA2507 - 10mM in DMSO , CAS No.1636894-46-6

CAS: 1636894-46-6 Cat. No.: K654456 Summenformel: C16H14N6O2 Molekulargewicht: 322.32 PubChem CID: 117703516
Zu bestellen verfügbar
QUALITÄT & REINHEIT 10mM in DMSO
Storage
Protected from light,Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1ml
K654456-1ml
Auf Bestellung · 8–12 Wochen
25,95€
Enter a quantity for the sizes you want to add.

Übersicht

KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC 50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models

In Vitro

KA2507 did not inhibit the in vitro proliferation of mouse or human cancer cells at concentrations that are selective for HDAC6 inhibition. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

KA2507 (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model . KA2507 also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models . Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I . KA2507 exhibits poor oral bioavailability (mice 15%) and C max (mice 300 ng/mL) following oral administration (mice 200 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6 mice, B16-F10 melanoma model Dosage: 100 mg/kg, 200 mg/kg, 200 mg/kg Administration: Oral gavage, daily, for 20 days Result: Demonstrated antitumor efficacy. Animal Model: Male C57BL/6 mice Dosage: 200 mg/kg (Pharmacokinetic Analysis) Administration: Oral administration Result: Oral bioavailability (15%), C max (300 ng/mL).

IC50& Target:HDAC6 2.5 nM (IC 50 ) HDAC8 621 (IC 50 )

Spezifikationen

Spezifikationen & Reinheit
10mM in DMSO
Biochemische und physiologische Mechanismen
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC 50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models.
Storage
Protected from light,Store at -80°C
Verschickt in
Dry ice packs + Cold packs
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Aktionsart
INHIBITOR
Namen und Kennungen
Isomere SMILES
C1=CC(=CC=C1CN(C2=NC=CN=C2)C3=NC=CN=C3)C(=O)NO
Alternative CAS-Nummer
1636894-46-6
PubChem CID
117703516
Molekulargewicht
322.32

Erweiterte Daten

Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Lösungsrechner
Bewertungen

Kundenbewertungen

Häufig gestellte Fragen

How should this product be stored?
Store at ?80 °C, protected from light. The material is light-sensitive — keep it in its original opaque or amber container.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1636894-46-6, the molecular formula is C16H14N6O2, and the molecular weight is 322.32 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.